Skip to main
ICUI

ICU Medical (ICUI) Stock Forecast & Price Target

ICU Medical (ICUI) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ICU Medical is a leading player in the infusion therapy market and is well-positioned for growth following its recent acquisitions. Its recent financial performance has been strong, with revenue, EBITDA, and EPS beating consensus estimates. The company's diverse product portfolio, strong financial profile, and potential for share capture make it an attractive investment opportunity. With a solid outlook for revenue growth and margin improvement, I have a positive outlook on the stock with a 12-month price target of $187, based on a P/E multiple of 20x our 2027E adjusted EPS estimate. However, there are some risks to this positive outlook, including potential pricing pressures and geopolitical instability.

Bears say

ICU Medical is facing potential upside drivers such as a pump upgrade cycle and new product launches, but also financial risks from gross margin pressure, uncertain pricing from contract renegotiations, and regulatory challenges. They also have strong potential for revenue and earnings growth and currently hold a number of buy ratings and price targets from other analysts on the market. However, there are concerns about potential challenges from their competitors and their reliance on the US market for a significant portion of their sales.

ICU Medical (ICUI) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICU Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICU Medical (ICUI) Forecast

Analysts have given ICU Medical (ICUI) a Buy based on their latest research and market trends.

According to 4 analysts, ICU Medical (ICUI) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $191, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $191, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICU Medical (ICUI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.